InvestorsObserver
×
News Home

Is Aslan Pharmaceuticals Ltd (ASLN) a Winner in the Biotechnology Industry?

Tuesday, July 20, 2021 11:04 AM | InvestorsObserver Analysts

Mentioned in this article

Is Aslan Pharmaceuticals Ltd (ASLN) a Winner in the Biotechnology Industry?

The 48 rating InvestorsObserver gives to Aslan Pharmaceuticals Ltd (ASLN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, ASLN’s 48 overall rating means the stock scores better than 48 percent of all stocks.

Overall Score - 48
ASLN has an Overall Score of 48. Find out what this means to you and get the rest of the rankings on ASLN!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 48 means the stock is more attractive than 48 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Aslan Pharmaceuticals Ltd Stock Today?

Aslan Pharmaceuticals Ltd (ASLN) stock is flat 0% while the S&P 500 has gained 1.28% as of 11:03 AM on Tuesday, Jul 20. ASLN is unmoved $0.00 from the previous closing price of $2.87 on volume of 293,547 shares. Over the past year the S&P 500 has gained 32.64% while ASLN has gained 47.94%. ASLN lost -$0.42 per share the over the last 12 months. Click Here to get the full Stock Report for Aslan Pharmaceuticals Ltd stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App